Operating cash flow was -$6.2M in 2026Q3 after a -$56.9M outflow in 2026Q2, suggesting the burn narrowed but working capital swings of -$54.9M in 2026Q1 indicate cash conversion remains unreliable.
Standard BioTools Inc. (LAB) cash flow statement — 20-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 |
|---|
| Cash from Operations | -64.27M | -74.35M | -143.45M | -43.29M | -89.37M | -44.06M | -15.42M | -35.21M | -25.2M | -24.1M | -39.1M | -34.7M | -22.62M | -1.59M | -17.48M | -17.54M | -11.51M | -19.51M | -28.72M | -21.76M | -22.31M |
| Operating CF Margin % | - | -87.13% | -82.24% | -40.71% | -91.24% | -33.74% | -11.16% | -30.03% | -22.31% | -23.64% | -37.43% | -30.25% | -19.43% | -2.24% | -33.4% | -40.92% | -34.29% | -76.79% | -187.14% | -299.09% | -348.64% |
| Operating CF Growth % | 159.98% | 48.17% | -231.4% | 51.56% | -102.83% | -185.79% | 56.21% | -39.72% | -4.58% | 38.37% | -12.69% | -53.37% | -1321.94% | 90.9% | 0.36% | -52.43% | 41.02% | 32.06% | -31.99% | 2.45% | - |
| Net Income | -39.21M | -74.9M | -138.88M | -74.66M | -190.1M | -59.24M | -53.02M | -64.79M | -59.01M | -60.53M | -75.98M | -53.31M | -52.83M | -15.82M | -19.02M | -22.47M | -16.9M | -19.13M | -29.5M | -25.45M | -23.55M |
| Depreciation & Amortization | 6.44M | 10.98M | 16.86M | 15.18M | 15.03M | 15.57M | 15.92M | 15.8M | 16.57M | 18.61M | 17.94M | 16.11M | 4.06M | 2.55M | 1.48M | 1.06M | 1.5M | 1.94M | 1.97M | 2.14M | 1.46M |
| Stock-Based Compensation | 22.34M | 29.61M | 31.73M | 13.12M | 14.88M | 16.1M | 14.45M | 11.39M | 11.02M | 9.09M | 13.86M | 16.83M | 20.94M | 6.44M | 4.09M | 2.8M | 1.59M | 2.11M | 2.02M | 708K | 145K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 212K | 0 | 141K | 0 | 0 | -2.33M | -332K | -1.78M | 0 | 23.37M | -10K | -1.9M | 14K | 0 | 0 |
| Other Non-Cash Items | -191.46M | 4.93M | -41.08M | 1.28M | 83.17M | 1.51M | 4.6M | 18.89M | 8.55M | -468K | 339K | -3.76M | 13.39M | 296K | 78K | -21.31M | 445K | 135K | -769K | 335K | 846K |
| Working Capital Changes | -34.66M | -44.98M | -12.08M | 1.79M | -12.35M | -18.01M | 2.41M | -16.51M | -2.48M | 9.2M | 4.75M | -8.23M | -7.85M | 6.72M | -4.1M | -990K | 1.87M | -2.67M | -2.46M | 511K | -1.2M |
| Change in Receivables | 8.77M | -1.36M | 8.97M | -2.99M | 1.06M | 6.73M | -7.63M | -2.08M | -1.79M | -554K | 10.52M | -2.76M | -3.39M | 2.41M | -3.7M | -1.22M | 209K | -4M | -3.28M | -135K | -400K |
| Change in Inventory | 1.68M | -11.52M | -9.88M | -4.91M | -8.47M | -4.78M | -8.64M | -3.05M | 1.49M | 4.6M | -3.39M | -3.74M | -6.16M | -1.53M | -1.68M | -1.08M | -961K | 1.51M | -20K | -2.46M | -955K |
| Change in Payables | -4.87M | 2.44M | 0 | 1.62M | 0 | 0 | 3.36M | 0 | -294K | 585K | -2.27M | 769K | 107K | 1.8M | -1.81M | 540K | 932K | -637K | 135K | 1.54M | -575K |
| Cash from Investing | 199.65M | 24.77M | 363.17M | 20.24M | -88.13M | -11.95M | 39.98M | -39.3M | 4.72M | 17.66M | 45.1M | 25.74M | -178.38M | -27.57M | 14M | -45.11M | -1.33M | -688K | 6M | -6.74M | -2.94M |
| Capital Expenditures | -1.39M | -8.3M | -8.36M | -2.83M | -3.83M | -13.26M | -12.72M | -2.53M | -372K | -1.62M | -5.07M | -10.65M | -7.4M | -4.69M | -2.38M | -1.68M | -1.54M | -799K | -910K | -973K | -2.93M |
| CapEx % of Revenue | 1.65% | 9.73% | 4.79% | 2.66% | 3.91% | 10.16% | 9.21% | 2.16% | 0.33% | 1.59% | 4.85% | 9.29% | 6.36% | 6.58% | 4.56% | 3.91% | 4.59% | 3.14% | 5.93% | 13.37% | 45.83% |
| Acquisitions | 22.49M | 0 | 278.65M | 0 | 0 | 0 | -5.15M | 0 | 0 | 50K | 2.33M | -2.33M | -112.86M | 3.12M | -14M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 386.3M | -5M | 92.88M | 0 | -84.3M | 1.32M | 21.04M | -36.77M | 5.09M | -50K | 50.17M | 2.33M | -57.79M | -24.12M | 14M | -2.02M | 206K | 111K | 625K | 19K | -8K |
| Cash from Financing | -156K | 570K | -102.62M | -6.81M | 230.76M | 15.96M | 20.86M | 2.79M | 57.66M | 29M | 76K | 5.3M | 200.33M | 5.81M | 48.52M | 70.37M | 3.8M | 16.94M | 6.33M | 37.55M | 31.12M |
| Debt Issued (Net) | 0 | 0 | -63.19M | -2.08M | 18.16M | 9.5M | 0 | 3.17M | 0 | 0 | 0 | 0 | 195.21M | 0 | -10.19M | -7.87M | 3.13M | 9.48M | 6.14M | 1.5M | 9M |
| Equity Issued (Net) | 346K | 1.05M | -40.95M | -5.55M | -774K | -1.79M | 20.23M | -629K | 59.47M | 28.79M | -111K | 0 | 5.11M | 0 | 56.01M | 76.95M | 633K | 7.41M | 0 | 35.91M | 21.93M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -598K | 0 | -40.95M | -5.41M | -774K | -1.79M | 0 | -629K | 0 | 0 | -111K | -151K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -69K |
| Other Financing | -502K | -484K | 1.52M | 827K | 213.37M | 8.25M | 631K | 245K | -1.81M | 204K | 187K | 5.3M | 0 | 5.81M | 2.7M | 1.29M | 39K | 53K | 180K | 147K | 190K |
| Net Change in Cash | 134.91M | -48.17M | 116.32M | -29.82M | 52.86M | -40.07M | 45.8M | -71.67M | 37.34M | 23.01M | 5.93M | -4.6M | -1.55M | -23.39M | 45.1M | 7.83M | -8.88M | -3.19M | -16.28M | 9.06M | 5.86M |
| Free Cash Flow | -65.66M | -82.65M | -151.81M | -46.12M | -93.19M | -57.33M | -28.13M | -37.74M | -25.57M | -25.71M | -44.16M | -45.35M | -30.03M | -6.28M | -19.86M | -19.22M | -13.05M | -20.31M | -29.63M | -22.73M | -25.24M |
| FCF Margin % | -77.76% | -96.86% | -87.03% | -43.37% | -95.15% | -43.9% | -20.37% | -32.19% | -22.64% | -25.23% | -42.28% | -39.53% | -25.78% | -8.82% | -37.95% | -44.83% | -38.88% | -79.93% | -193.07% | -312.47% | -394.47% |
| FCF Growth % | 33.29% | 45.55% | -229.18% | 50.51% | -62.57% | -103.76% | 25.46% | -47.58% | 0.55% | 41.77% | 2.61% | -51.03% | -378.35% | 68.4% | -3.35% | -47.3% | 35.77% | 31.45% | -30.34% | 9.93% | - |
| FCF per Share | -0.17 | -0.22 | -0.43 | -0.58 | -1.19 | -0.76 | -0.39 | -0.57 | -0.64 | -0.78 | -1.52 | -1.58 | -1.08 | -0.25 | -0.90 | -1.08 | -0.69 | -11.70 | -17.92 | -12.03 | -13.35 |
| FCF Conversion (FCF/Net Income) | 1.67x | 0.99x | 1.03x | 0.58x | 0.47x | 0.74x | 0.29x | 0.54x | 0.43x | 0.40x | 0.51x | 0.65x | 0.43x | 0.10x | 0.92x | 0.78x | 0.68x | 1.02x | 0.97x | 0.85x | 0.95x |
| Interest Paid | 8K | 15K | 3.09M | 3.82M | 3.49M | 3.15M | 3.09M | 3.54M | 5.53M | 5.53M | 5.53M | 5.54M | 2.75M | 7K | 579K | 1.72M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 1.02M | 0 | 0 | 801K | 0 | 0 | 521K | 0 | 321K | 245K | 355K | 189K | 187K | 242K | 181K | 42K | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LAB stock.
Standard BioTools Inc. (LAB) generated $-74.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Standard BioTools Inc. (LAB) reported negative free cash flow of $82.7M in 2025, indicating capital requirements exceeded cash from operations.
Standard BioTools Inc. (LAB) spent $8.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Earnings Repeatedly Diverge From Operating Cash
As reported in the quarterly cash flow statements, LAB's operating cash flow was negative in most of the ten quarters, while net income swung widely and turned positive in 2026Q3 at $13.5M against operating cash outflow of -$6.2M.
The 2026Q3 profit coinciding with an OCF/NI ratio of -0.46 suggests non-cash gains or working capital movements are inflating reported earnings rather than reflecting cash generation. Across most quarters the OCF/NI ratio swung between 0.41 and 2.13, indicating the two measures are driven by different forces and that net income is not a reliable proxy for operating performance. Investors should monitor whether the earnings-to-cash gap narrows as the business stabilizes.
Free Cash Flow Deeply Negative Throughout
Based on reported figures, LAB's free cash flow margin reached -182.2% in 2024Q2 and -174.7% in 2025Q1, with the most recent quarter at -31.8%, showing sustained cash consumption relative to revenue even as the burn rate moderated.
Free cash flow was negative in every quarter presented, and the margin compression toward -31.8% in 2026Q3 appears to reflect a shrinking revenue base more than a structural turn in cash generation. The 2026Q2 FCF deficit of -$57.8M shows the burn remained material relative to the company's scale. Without a sustained run of positive FCF, the business appears dependent on existing balance sheet resources, which warrants further investigation.
Volatile Capex Raises Maintenance Questions
As reported in the cash flow statements, LAB's capital expenditures ranged from zero to $5.1M per quarter, with CapEx-to-revenue reaching 25.0% in 2025Q1 before falling to 2.0% in 2025Q4, suggesting spending is discretionary and uneven rather than steady.
The sharp decline in capex from 2025Q1 to 2025Q4 may reflect deliberate spending restraint rather than a completed build-out, so recent low figures may not represent a sustainable maintenance baseline. Depreciation and amortization of $1.4M to $5.6M per quarter indicates the installed asset base requires some ongoing reinvestment. Investors should monitor whether capex stays suppressed for an extended period, as that could defer necessary asset replacement.
Working Capital Swings Dominate Quarterly Cash
According to the reported figures, LAB's working capital changes ranged from -$54.9M in 2026Q1 to +$8.7M in 2024Q4, and these movements appear to account for a large share of quarterly operating cash variance.
The 2026Q1 working capital outflow of $54.9M coincided with a -$46.6M operating cash flow quarter, indicating balance sheet timing rather than core operating losses may have driven much of that shortfall. The reversal to a +$4.9M inflow in 2026Q3 suggests these swings are substantial and difficult to forecast from the data alone. Investors should monitor receivables, inventory, and payables trends to determine whether the pattern reflects timing noise or a recurring drain.
Acquisition Inflow Unexplained by Reported Data
Based on the reported figures, LAB recorded a net acquisition-related inflow of $363.2M in 2026Q1 alongside no dividend payments and only minor buybacks, suggesting capital deployment has been limited during the period.
The $363.2M net acquisition figure in 2026Q1 is unusually large relative to the company's cash flow scale, and the supplied data does not explain its source, so it warrants further investigation. Dividends were nil throughout and buybacks were small or absent, which is consistent with a company preserving cash rather than returning it. Whether this inflow materially strengthens liquidity cannot be determined from the cash flow data alone.
Cash Burn Narrative May Overstate Deterioration
As reported in the cash flow statements, LAB's operating cash outflow narrowed from -$56.9M in 2026Q2 to -$6.2M in 2026Q3, and the bear case may rest on a single quarter's working capital reversal rather than a durable trend.
The 2026Q3 improvement was driven substantially by a +$4.9M working capital inflow and falling SG&A, so bears may argue this is non-recurring rather than evidence of a sustained turn. Conversely, the cumulative FCF deficit across the ten quarters and the absence of any disclosed dividends or buybacks limit the cash-generation case, and the cash flow data alone does not establish whether the recent narrowing will hold.